Group 6G: HR+ Breast Cancer; Hormone Therapy; Novel Targets & Treatments



Thursday, Dec 15 6:00 pm – 7:30 pm Eastern Time (US/New York)



Poster #OT2-01-04

ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer

Poster #PD13-12:

Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study

Mentor: Terri Shipp, M.S.

Terri Shipp shares a passion for science and the education of women affected by breast cancer.  She was personally affected by the disease as a young woman and 12 years later was diagnosed with metastatic breast cancer.  She holds a master’s degree in science in the field of electrical engineering and has actively attended many conferences and seminars on breast cancer.

She graduated in 2022 from Living Beyond Breast Cancer’s (LBBC) Hear My Voice Metastatic Advocacy Program and the National Breast Cancer Coalition’s Project LEAD Program.  She also supports METAvivor’s Michigan #LightUpMBC and the Stage IV Stampede teams.

In 2021, she became an advocate for GRASP and has participated in multiple poster reviews with the authors of various scientific studies.  This year, she moved to the mentor advocate roll. She is excited to be a part of these program.

Scientist: Diego Pedroza, Ph.D.

Twitter: @Dapedroza11